Amendments To Canada's Special Access Program (SAP) Allows Access To Restricted Psychedelic Drugs. How Will This Affect The Industry?

Mental health professionals have been exploring psychedelics as a treatment for substance abuse and mental health disorders for decades, and now its status as a legitimate treatment is being recognized in Canada.

An amendment to Canada’s Special Access Program (SAP) allows access to restricted psychedelic drugs like psilocybin, MDMA, LSD, and DMT for patients with a “serious or life-threatening condition” where conventional treatments have failed.

While the amendment is considered by some to be a step forward, the government has said it doesn’t mean psychedelics are headed toward decriminalization or legalization. The vague language also means that many patients in need may not qualify for special access.

One company that is examining psychedelics in the treatment of mental health disorders is MINDCURE Mental Health Inc., a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health.

Read More